Literature DB >> 11876755

Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis.

I J Messias-Reason1, S Y Hayashi, R M Nisihara, M Kirschfink.   

Abstract

In an infectious process complement activation is necessary for a proper immune and inflammatory response, but when exacerbated may cause tissue injuries. In infective endocarditis (IE) patients tend to develop high titres of circulating immune complexes (CIC) that activate complement. The aim of this study was to evaluate for the first time complement activation in IE for possible correlation with extracardiac manifestations and clinical prognosis. Twenty patients with IE, 14 healthy controls and 15 patients presenting mitral and aortic valve lesions (with no signs of either infection or other associated diseases), were studied. Plasma levels of C3adesArg, SC5b-9, C1rs-C1Inh and C3b(Bb)P were determined by ELISA and C3d by double decker immunoelectrophoresis. C3 and C4 levels were assayed by turbidimetry and CIC by ELISA. Elevation of plasma levels of all complement activation products, with the exception of C3b(Bb)P, indicated a significant classical pathway activation in IE patients when compared to controls (C3d: P < 0.00004; C3adesArg: P < 0.03, SC5b-9: P < 0.01, C1rs-C1Inh: P < 0.00007). CIC levels were significantly increased (P < 0.005) and C3 reduced in IE patients (P < 0.05). Elevated C3d (P < 0.02) and C3adesArg (P < 0.03) levels were associated with pulmonary manifestations. In addition, C3d was significantly elevated in the patients who died when compared to those who had a good recovery (P < 0.02). Our data demonstrate the activation of the complement classical pathway, most probably mediated by CIC, in IE and suggests C3d and C3adesArg as possible markers for extracardiac lesion and severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11876755      PMCID: PMC1906352          DOI: 10.1046/j.1365-2249.2002.01772.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity.

Authors:  N W Lukacs; M M Glovsky; P A Ward
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-03       Impact factor: 5.464

2.  Detection and partial characterization of circulating immune complexes with solid-phase anti-C3.

Authors:  A B Pereira; A N Theofilopoulos; F J Dixon
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

3.  The clinical implications and the pathogenetic significance of circulating immune complexes in infective endocarditis.

Authors:  R H Kauffmann; J Thompson; R M Valentijn; M R Daha; L A Van Es
Journal:  Am J Med       Date:  1981-07       Impact factor: 4.965

4.  Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma.

Authors:  I Brandslund; H C Siersted; S E Svehag; B Teisner
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

5.  Circulating immune complexes and severe sepsis: duration of infection as the main determinant.

Authors:  M A Pocidalo; C Gibert; P Verroust; M Geniteau; C Adam; Y Madec; C Gaudebout; L Morel-Maroger
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

6.  Nature of circulating immune complexes in infective endocarditis.

Authors:  J Burton-Kee; P Morgan-Capner; J F Mowbray
Journal:  J Clin Pathol       Date:  1980-07       Impact factor: 3.411

7.  Circulating immune complexes in experimental streptococcal endocarditis: a monitor of therapeutic efficacy.

Authors:  A S Bayer; A N Theofilopoulos; F J Dixon; L B Guze
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

8.  Inhibition of immune precipitation by complement.

Authors:  J A Schifferli; S R Bartolotti; D K Peters
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

9.  Infective endocarditis-associated glomerulonephritis in rabbits: evidence of a pathogenetic role for antiglobulins.

Authors:  M Sindrey; J Barratt; J Hewitt; P Naish
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

10.  Serum and tissue immune complexes in infective endocarditis.

Authors:  P E McKenzie; D Hawke; A J Woodroffe; A J Thompson; A E Seymour; A R Clarkson
Journal:  J Clin Lab Immunol       Date:  1980-11
View more
  5 in total

1.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

2.  Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.

Authors:  M Abdel-Latif; A A Abdel-Moneim; M H El-Hefnawy; R G Khalil
Journal:  Clin Exp Immunol       Date:  2017-07-13       Impact factor: 4.330

3.  Infective endocarditis initially manifesting as pseudogout.

Authors:  Tim Brotherton; Chad S Miller
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-09

4.  Successful treatment of infectious endocarditis associated glomerulonephritis mimicking c3 glomerulonephritis in a case with no previous cardiac disease.

Authors:  Yosuke Kawamorita; Yoshihide Fujigaki; Atsuko Imase; Shigeyuki Arai; Yoshifuru Tamura; Masayuki Tanemoto; Hiroshi Uozaki; Yutaka Yamaguchi; Shunya Uchida
Journal:  Case Rep Nephrol       Date:  2014-11-23

5.  IgM cleavage by Streptococcus suis reduces IgM bound to the bacterial surface and is a novel complement evasion mechanism.

Authors:  Viktoria Rungelrath; Christine Weiße; Nicole Schütze; Uwe Müller; Marita Meurer; Manfred Rohde; Jana Seele; Peter Valentin-Weigand; Michael Kirschfink; Andreas Beineke; Wieland Schrödl; René Bergmann; Christoph Georg Baums
Journal:  Virulence       Date:  2018       Impact factor: 5.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.